Praneeth Baratam

Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors

Ali Raza Khaki, Ang Li, Leonidas Nikolaos Diamantopoulos et al. · Cancer · 2019 · 90 citations · Full text

Medicine, Oncology, Urology +16

Final phase 1 substudy results of ivosidenib for patients with mutant <i>IDH1</i> relapsed/refractory myelodysplastic syndrome

Courtney D. DiNardo, Gail J. Roboz, Justin M. Watts et al. · Blood Advances · 2024 · 44 citations · Full text

Medicine, Hematology, Pharmacology +14

Case report of rhabdomyosarcomatous transformation of a primary gastrointestinal stromal tumor (GIST)

Li L, Marian Khalili, Gregg J. Johannes et al. · BMC Cancer · 2019 · 14 citations · Full text

Medicine, Oncology, Pathology +17

Ivosidenib in patients with <i>IDH1</i>-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy.

David A. Sallman, James M. Foran, Justin M. Watts et al. · Journal of Clinical Oncology · 2022 · 10 citations

Medicine, Pharmacology, Pharmacotherapy +15